Description

Buy 3-Methylmethcathinone (3-MMC) Cas 1246911-86-3

3-Methylmethcathinone (3-MMC), also known as metaphedrone,^[4] is a designer drug from the substituted cathinone family. 3-MMC is a monoamine transporter substrate (a substance acted upon by monoamine transporters in the brain) that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity.^[5][6] 3-Methylmethcathinone is a structural isomer of mephedrone (4-methylmethcathinone), and as such is illegal via blanket bans in many countries that have banned mephedrone. However, 3-MMC has still appeared on the recreational drug market as an alternative to mephedrone, and was first identified being sold in Sweden in 2012.^[7] Unlike some other synthetic cathinones, 3-MMC has been evaluated in at least one large mammal study.^[2]

As with mephedrone, users of 3-MMC typically report effects such as an elevated mood, pleasant body sensations, feelings of love and empathy, euphoria, greater appreciation of music, heightened libido, and increased confidence and sociability.^[8] Adverse effects range from aggression, dry mouth, and jaw clenching, to more serious effects such as hyponatremia, seizures, hyperthermia and rhabdomyolysis.^[8][9] Due to its fleeting duration and dopaminergic effects, 3-MMC is highly addictive and commonly abused. Repeated dosing within a sitting is typical, sometimes using different routes, primarily oral and intranasal. Common self-reported doses range from 50 to 150 mg, up to single 500 mg doses. Intranasal administration, or snorting, is the most common route of administration, followed by oral administration, followed by other routes, such as rectal administration and injection into the bloodstream. Users may dose repeatedly in order to extend the drugs duration, leading to 0.5—2 gram "sessions" that can span an evening. Single-dose effects last from 30 to 60 minutes, typically peaking around 10-minutes post-dose. In a questionnaire-based study of self-reported 3-MMC users in Slovenia, it was found that 88% of users insufflated the drug while 42% took it orally. The study did not find any instances of users injecting 3-MMC. Moreover, 26% of the users reported taking more than 1.5 grams of 3-MMC in a single sitting and over 50% reported having consumed more than 0.5 grams in a single sitting.^[10] 3-Methylmethcathinone is commonly encountered as a white/off-white crystalline or pasty solid. It can be found sold in capsules. It is assumed to be a racemic mixture like mephedrone. Side effects of 3-MMC include increased heart rate, increased blood pressure, and decreased appetite.^[11] A total of 27 fatalities with at least some exposure to 3-MMC have been confirmed as of March 2022. Eighteen of the 27 reported fatalities involved multiple drugs of abuse, usually opioids and uppers ("speedballs").^[12] Of the 13 cases that specified sex, 12 deaths were male and 1 death was female. Of the 7 males whose age was reported, the median age was 27. The fatalities see a wide range of blood concentrations, from 249 to 1600 ng/mL.^[13] The route of administration in any of these fatalities is not clear. Of the presumably nine monointoxication deaths involving only 3-MMC that have occurred, two monointoxication cases were reported in the Netherlands and one was reported in France. The death in France was determined to be an accidental overdose. In addition, there has been 291 reported cases of non-fatal 3-MMC intoxications. 213 of these cases (75%) were reported in Poland alone, and 50 cases (17%) were reported in Sweden. The toxicokinetics of 3-MMC are thought to be similar to those for mephedrone. The first human study conducted in 14 healthy human volunteers concluded that "...low to moderate doses of 3-MMC were well tolerated and safe and that potential health risks might only occur at high or excessive doses of 3-MMC."^[14]